Granted
The Board granted a rating of 60 percent for interstitial lung disease, both prior to and from November 10, 2022.
The deciding factor: The evidence was at least in approximate balance as to whether the Veteran's sarcoidosis manifested in pulmonary involvement requiring systemic high dose corticosteroids for control during the relevant periods.
- Claimed conditions
- Interstitial lung disease, Sarcoidosis
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- 60%
- Decision date
- February 19, 2025
- Citation
- 25002432
Want to see how appeals like this one tend to go? Appeals like mine
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.